Breaking new ground to build bone

Proceedings of the National Academy of Sciences of the United States of America

Volumn 104, Issue 26, 2007, Pages 10753-10754

  Kingsley, Lauren A ^a   Chirgwin, John M ^a   Guise, Theresa A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN; CALCITONIN; DKK1 ANTIBODY; ESTROGEN; FLUOROALUMINATE; FOCAL ADHESION KINASE 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NEUTRALIZING ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE[1-34]; PF 431396; PROTEIN; PROTEIN KINASE INHIBITOR; SCLEROSTIN; SCLEROSTIN ANTIBODY; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SHORT HAIRPIN RNA; STRONTIUM; UNCLASSIFIED DRUG; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BONE; BONE CANCER; BONE DENSITY; BONE INJURY; BONE MASS; BONE MINERAL; BONE MINERALIZATION; BONE NECROSIS; BONE REMODELING; CANCER PATIENT; CANCER RISK; CELL DIFFERENTIATION; CELL MATURATION; CELL MOTILITY; CONTROLLED STUDY; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG LABELING; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ENZYME PHOSPHORYLATION; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FOOD AND DRUG ADMINISTRATION; FRACTURE; FRACTURE HEALING; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; MESENCHYMAL STEM CELL; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; NOTE; ONCOGENE SRC; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSARCOMA; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RAT; TUMOR GROWTH;

ANIMALS; ENZYME INHIBITORS; FOCAL ADHESION KINASE 2; HUMANS; OSTEOGENESIS; OSTEOPOROSIS;

EID: 34547429368     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.0704357104     Document Type: Note

References (20)

1. Harvey N, Earl S, Cooper C (2006) in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, ed Favus MJ (Am Soc Bone and Mineral Res, Washington, DC), pp 244-248.
2. Shoback D (2007) J Clin Endocrinol Metab 92:747-753.
3. Buckbinder L, Crawford DT, Qi H, Ke HZ, Olson LM, Long KR, Bonnette PC, Baumann AP, Hambor JE, Grasser WA, III, et al. (2007) Proc Natl Acad Sci USA 104:10619-10624.
4. Avraham H, Park SY, Schinkmann K, Avraham S (2000) Cell Signal 12:123-133.
5. Duong LT, Lakkakorpi P, Nakamura I, Rodan GA (2000) Matrix Biol 19:97-105.
6. Lakkakorpi PT, Bett AJ, Lipfert L, Rodan GA, Duong LT (2003) J Biol Chem 278:11502-11512.
7. Duong LT, Lakkakorpi PT, Nakamura I, Machwate M, Nagy RM, Rodan GA (1998) J Clin Invest 102:881-892.
8. Shyu JF, Shih C, Tseng CY, Lin CH, Sun DT, Liu HT, Tsung HC, Chen TH, Lu RB (2007) Bone 40:1329-1342.
9. Okigaki M, Davis C, Falasca M, Harroch S, Felsenfeld DP, Sheetz MP, Schlessinger J (2003) Proc Natl Acad Sci USA 100:10740-10745.
10. Kim JB, Leucht P, Luppen CA, Park YJ, Beggs HE, Damsky CH, Helms JA (2007) Bone, in press.
11. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, et al. (2001) N Engl J Med 344:1434-1441.
12. Bilezikian JP, Rubin MR, Finkelstein JS (2005) J Endocrinol Invest 28:41-49.
13. Girotra M, Rubin MR, Bilezikian JP (2006) Rev Endocr Metab Disord 7:113-121.
14. Rubin MR, Bilezikian JP (2005) Drugs 65:2481-2498.
15. Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ, McCauley LK (2005) Endocrinology 146:1727-1736.
16. Tashjian AH, Jr, Gagel RF (2006) J Bone Miner Res 21:354-365.
17. Balemans W, Van Hul W (2004) J Musculoskelet Neuronal Interact 4:139-142.
18. Ott SM (2005) J Clin Endocrinol Metab 90:6741-6743.
19. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G (1999) Science 286:1946-1949.
20. Jadhav SB, Jain GK (2006) J Pharm Pharmacol 58:3-18.